Antibody production services market seen topping $11.45 billion by 2030

The antibody production services market is forecast to grow from $6.44 billion in 2025 to $7.24 billion in 2026, with demand rising across research, diagnostics and therapeutics. The Business Research Company says chronic disease prevalence, biologics pipelines and outsourcing by drugmakers are key drivers, while North America leads and Asia-Pacific is set to grow fastest.

Why it matters: - Antibody production services support biomedical research, diagnostics and therapeutic development. - Faster demand could help drugmakers and research organizations access more customized, high-quality antibodies. - The market's growth tracks broader pressure from chronic disease, biologics development and personalized medicine.

What happened: - The Business Research Company released a forecast report on the global antibody production services market. - The market is projected to rise from $6.44 billion in 2025 to $7.24 billion in 2026. - The forecast implies a 12.4% CAGR in 2026. - The market is expected to reach $11.45 billion by 2030. - The longer-term forecast points to a 12.1% CAGR through 2030. - The report is available as a free sample and as the full market report.

The details: - Antibody production services create polyclonal and monoclonal antibodies targeted to specific antigens. - The services are used for detection, measurement and neutralization of proteins or pathogens. - The report links past growth to expanding biomedical research, rising demand for monoclonal antibody therapies, wider diagnostic use, increased life sciences investment and improved antibody engineering technologies. - The report links future growth to personalized medicine, biologics pipelines, outsourcing by pharmaceutical companies, advances in antibody formats and a stronger focus on reproducibility and quality control. - Key trends cited for the forecast period include customized antibody generation, recombinant antibody adoption, demand for high-affinity and high-specificity antibodies, growth in outsourced production and tighter quality validation standards. - The report says chronic disease prevalence is a major demand driver. - The report cites the UK National Health Service as reporting 3,615,330 diagnoses of non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 in 2022. - The report says sedentary lifestyles contribute to higher risks of heart disease and diabetes. - In 2025, North America held the largest share of the market. - Asia-Pacific is projected to post the fastest growth rate during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast points to a market shifting from broad research support toward more specialized and outsourced production. - Stronger quality control and reproducibility demands suggest customers are prioritizing reliability over volume alone. - Regional growth outside North America may reflect faster expansion in research capacity, drug development and healthcare investment. - The report's emphasis on customized and recombinant antibodies signals rising demand for more precise tools in both diagnostics and therapeutics.

What's next: - Demand is likely to stay tied to chronic disease trends, biologics development and personalized medicine. - Pharma outsourcing could keep expanding as companies try to speed development and reduce internal manufacturing pressure. - The market will likely favor providers that can deliver validated, high-affinity antibodies with consistent quality. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics and updated trend graphics.

The bottom line: - Antibody production services are moving into a bigger, more specialized market, with growth driven by chronic disease, biologics and the push for better research and therapeutic tools.